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Abstract. Norepinephrine is a potent α-sympathomimetic drug which plays an important
role in the acute treatment of hypotension and shock. Commercially available norepineph-
rine solutions contain sodium metabisulfite (Na2S2O5) as an antioxidant. However, prefilled
cyclic olefin polymer syringes are not compatible with sodium metabisulfite. The aim of this
study was to develop a new formulation of 0.1-mg/mL norepinephrine solution without
sodium metabisulfite which is chemically stable and sterile and can be stored in prefilled
polymer syringes. Formulation studies were performed with 0.1-mg/mL norepinephrine
solution with 0, 0.05, or 0.1% ascorbic acid added as antioxidant. The syringes were filled
under nitrogen gassing, stored at 20 ± 5°C, and protected from daylight. Based on the
formulation test results, the final formulation was defined and stability testing at 20 ± 5°C was
performed measuring norepinephrine concentration, pH, clarity, color of the solution,
subvisible particles, and sterility at time intervals up to 12 months. The norepinephrine
concentrations at t = 22 weeks were 100.4%, 95.4%, and 92.2% for the formulations with no
ascorbic acid and with 0.05% and 0.10% ascorbic acid, respectively. Three batches for the
stability study were produced containing norepinephrine, sodium edetate, sodium chloride,
and water for injections filled under nitrogen gassing and stored at 20 ± 5°C. Norepinephrine
concentrations were respectively 98.8%, 98.6%, and 99.3% for batches 1, 2, and 3 at t =
12 months. It can be concluded that norepinephrine (0.1 mg/mL) solution without
metabisulfite is stable for at least 12 months at room temperature when protected from
daylight.
KEY WORDS: norepinephrine; stability; antioxidant; syringe.
INTRODUCTION
Norepinephrine is a potent α-sympathomimetic drug
which plays an important role in the acute treatment of
hypotension and shock. In most European countries, com-
mercially available preparations contain 1 or 5 mg/mL
norepinephrine supplied as vials. Usually, the injection is
diluted with sodium chloride 0.9% before administration.
Preparation and administration of parenteral medication in
the hospital setting are associated with error rates up to 48%
(1–3). Providing ready-to-administer medication prepared in
the pharmacy department has been suggested frequently to
reduce medication errors (4,5). This is implemented in
hospitals across Europe (6,7). A new development in this
area is ready-to-administer prefilled sterilized syringes (PFSS)
produced by the hospital pharmacy. The use of PFSS
products eliminates the preparation step in the ward, thereby
preventing medication errors (4,8).
In The Netherlands, norepinephrine concentrations of
0.05, 0.1, 0.2, or 0.4 mg/mL are available as ready-to-use
products (vials) but not as ready-to-administer syringes. Due
to the catechol substructure, norepinephrine can easily
undergo oxidation resulting in the formation of adrenolutines,
adrenochromes, and oxadrenochromes (the typical black-
colored insoluble particles). This process is catalyzed by light,
oxygen, elevated temperatures, heavy metals, basic condi-
tions, and several excipients (9). In order to prevent the
degradation and discoloration, commercially available prod-
ucts are manufactured in brown glass vials, airtight sealing,
blanketing with nitrogen, addition of metal chelators such as
ethylenediamine tetraacetic acid (EDTA), and addition of
antioxidants such as sulfites or ascorbic acid, and they are to
be stored at low temperatures (10). For optimum stability, a
1 Department of Clinical Pharmacy, Isala, Dokter van Heesweg 2,
8025 AB, Zwolle, The Netherlands.
2 Unit of PharmacoTherapy, -Epidemiology & PharmacoEconomics
(PTE2), Groningen Research Institute of Pharmacy, University of
Groningen, Groningen, The Netherlands.
3 Department of Pharmaceutical Technology and Biopharmacy,
University of Groningen, Groningen, The Netherlands.
4 To whom correspondence should be addressed. (e–mail:
k.h.m.beld@isala.nl)
Abbreviations: COP, Cyclic olefin polymer; EDTA, Ethylenediamine
tetraacetic acid; PFSS, Prefilled sterilized syringes.
AAPS PharmSciTech (2020) 21: 247
DOI: 10.1208/s12249-020-01784-z
1530-9932/20/0700-0001/0 # 2020 The Author(s)
pH range of 3.6–6.0 is recommended for the norepinephrine
solution (10,11). All commercially available norepinephrine
solutions contain sodium metabisulfite (Na2S2O5) as an
antioxidant. However, the cyclic olefin polymer syringes used
for delivering ready-to-administer syringes are not compatible
with sodium metabisulfite due to brown colorization of the
syringes during sterilization. A further disadvantage of
sodium metabisulfite is the possible adverse events due to
sulfite hypersensitivity of patients which can result in
symptoms varying from mild discomfort up to life-
threatening episodes and even death (12,13). In a recently
published systematic review, various results have been found
about the stability of epinephrine (14).
The purpose of this study was to develop a formulation
of 0.1-mg/mL norepinephrine solution for use in prefilled
syringes which is chemically stable and sterile and which is
free of sodium metabisulfite.
MATERIALS AND METHODS
Materials
Norepinephrine tartrate monohydrate was obtained from
Cambrex Profarmaco Milano Srl (Milan, Italy). The formu-
lation contained the following excipients: sodium edetate
(Akzo Nobel Functional Chemical, Arnhem, Netherlands)
and sodium chloride (ESCO France SAS, Dombasle, France).
Ascorbic acid was purchased from Celanese, Denmark.
The cyclic olefin polymer (COP) syringes used were the
BD Sterifill Advance™ 50-mL syringes from Becton Dickin-
son (BD) Medical Pharmaceutical systems, with a Luer Lock
Adaptor and screwed tip cap. Filled syringes were closed with
a bromobutyl plunger stopper from Datwyler.
Preparation Test Solutions
Formulation tests were performed with 0.1-mg/mL
norepinephrine solutions containing 0.1 mg/mL sodium
edetate, 8 mg/mL sodium chloride, and water for injections.
To this solution 0, 0.05, or 0.1% ascorbic acid was added as an
antioxidant. The test solutions were prepared on a laboratory
scale and filled under nitrogen gassing. The filled syringes
were not sterilized. The syringes were stored at room
temperature (20 ± 5°C), protected from daylight. The norepi-
nephrine concentration was determined after storage for 0, 1,
3, 7, 13, and 22 weeks.
For stability testing, 3 batches were produced. The
formulation contained norepinephrine 0.11 mg/mL, sodium
edetate 0.1 mg/mL, sodium chloride 8 mg/mL in water for
injections. An overage of 10% norepinephrine was used for
batch 1 and 2 because historical data show a loss of
norepinephrine during the sterilization process. For batch 3,
the overage was reduced to 5% because the loss in the
validation batches 1 and 2 was less than expected. See also
Table I for the formulation composition for testing and
stability batches. Acceptance criteria for release were 95–
105%; for the stability study, these were 90–110% based on a
declaration of norepinephrine of 0.1 mg/mL. The norepi-
nephrine solution was produced in a 400-L stainless steel
vessel. The pH of the bulk solution was set to 3.8–3.9 (with
10% HCl or 2-M NaOH solutions), and the oxygen level in
the solution was reduced to < 1% by nitrogen gassing. The
syringes were filled with a semi-automatic filling and closing
machine, filling and stopper placement were performed under
nitrogen gassing. The syringes were terminally sterilized for
15 min at 121°C. For stability testing, performed after storage
at 20 ± 5°C, the following parameters were determined:
norepinephrine concentration, pH, clarity, color of solution,
subvisible particles, and sterility. The time intervals were
according to ICH guidelines (16).
Analytical Method
Analysis of Norepinephrine
The UHPLC system Agilent 1290 Infinity (Agilent,
Santa Clara, California, USA) comprised an Agilent
G4220A Binary Pump, an Agilent G4226A Autosampler, an
Agilent G1316C Column Compartment, and an Agilent
G4212A Diode Array Detector. The Agilent OpenLab CDS
(EZChrom edition) was used as a processing module to
obtain the results of this study. The chromatographic separa-
tions were performed on a Kinetex Biphenyl column
(Phenomenex, Torrance, California, USA) with the following
dimensions: particle diameter 2.6 μm, size 3.0 × 100 mm. The
mobile phase consists of a mixture of deionized water
(Millipore, Burlington, Massachusetts, USA); acetonitrile,
HPLC gradient grade (Boom, Meppel, The Netherlands);
and trifluoroacetic acid, reagent grade (Merck, Darmstadt,
Germany). The mobile phase consisted of an acidified (0.1%
trifluoroacetic acid) deionized water (solution A) partly
mixed with a solution of 20% acetonitrile and 80% deionized
water (solution B). The ratio of the mobile phase was set at
98.0% solution A and 2.0% solution B with a flow of 0.4 mL/
min to obtain the isocratic separation of the components in
the formulated samples. The injection volume was set at 5 μl.
The temperature of the autosampler and column compart-
ment was set at 10°C and 30°C respectively. A washing fluid
of 5% acetonitrile was used to avoid sample carryover. Peaks
were detected at a wavelength of 280 nm. The performance
has been monitored by the analysis of a system suitability
solution which contained norepinephrine (50 mg/L) and
epinephrine (25 mg/L). Parameters such as retention time,
resolution, and symmetry factor verified the suitability of the
system. The standard solution containing norepinephrine
50 mg/L was freshly prepared for each calibration curve.
Samples were diluted with deionized water to obtain a final
concentration of around 50 mg/L.
Validation of the Analytical Method
The stability-indicating nature of the analytical method
was confirmed by subjecting norepinephrine to thermal,
photolytic, oxidative, and hydrolytic stress conditions. Nor-
epinephrine (0.1 mg/mL) solutions stressed by hydrogen
peroxide 0.1%, hydrochloric acid 0.06 M, or sodium hydrox-
ide 0.06 M were filled into BD Sterifill Advance™ 50-mL
syringes. To test the thermal condition, stressed and reference
solutions were stored at 80°C and analyzed for the norepi-
nephrine concentration. The temperature of 80°C was chosen
because this was the highest possible temperature to perform
the test, and also because the expected degradation will occur
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at this temperature (10). Test solutions were analyzed
conform to the UHPLC method described above, with no
interfering peaks being detected, demonstrating the selectiv-
ity of the analytical method.
Further validation was performed to demonstrate linear-
ity, accuracy, and precision of the method according to ICH
guidelines (16). For the linearity, the calibration curve was
prepared using the peak areas obtained from the chromato-
grams of the injections with a known concentration of
norepinephrine in a range of 25.0 to 75.0 mg/L. The
relationship of peak area to concentration was found to be
linear throughout the studied concentration range. The
accuracy was determined at 3 levels of norepinephrine
(0.05 mg/mL, 0.10 mg/mL, 0.15 mg/mL). An average recovery
between 97.0 and 103.0% was obtained. The determination of
the intermediate precision was performed on different days,
with varying materials and systems. The relative standard
deviation of the repeatability of the method was ≤ 2.0%. The
average pooled standard deviation of the intermediate
precision was ≤ 5.0%.
Acceptance Criteria Norepinephrine Solution
According to different monographs of the European
Pharmacopoeia and ICH guideline Q6A, several tests were
performed in the stability study. An overview of the
performed tests is given in Table II. No tests on impurities
and extractables were performed due to an extensive
qualification program performed for the primary container
(17), and the raw materials used in the production process.
All active pharmaceutical ingredients (API) raw material are
approved in advance by the manufacturer with a certificate of
Table I. Formulation Composition of Norepinephrine Solution
Norepinephrine Concentration Antioxidant Osmotic agent
Formulation tests
Batch 1 0.1 mg/mL 0.1 mg/mL sodium edetate
No ascorbic acid
8 mg/mL sodium chloride
Batch 2 0.1 mg/mL 0.1 mg/mL sodium edetate
0.05% ascorbic acid
8 mg/mL sodium chloride
Batch 3 0.1 mg/mL 0.1 mg/mL sodium edetate
0.1% ascorbic acid
8 mg/mL sodium chloride
Stability study
Batch 1 0.110 mg/mL 0.1 mg/mL sodium edetate 8 mg/mL sodium chloride
Batch 2 0.110 mg/mL 0.1 mg/mL sodium edetate 8 mg/mL sodium chloride
Batch 3 0.105 mg/mL 0.1 mg/mL sodium edetate 8 mg/mL sodium chloride
Table II. Acceptance Criteria Norepinephrine Solution
Test Monograph Description/acceptance limit
1. Clarity and degree of opalescence
of the solution
Ph. Eur. 2.2.1. The clarity of the solution is the same as that
of water R. The absence of any particles or
inhomogeneity’s in a solution results in a
clear solution.
2. Degree of coloration of the solution Ph. Eur. 2.2.2 Examination of the degree of coloration of the
solution in the range brown-yellow-red; ≤ B9
3. pH of the solution Ph. Eur. 2.2.3 3.6–6.0
4. Identity sodium Ph. Eur 2.3.1 Positive
5. Concentration norepinephrine UHPLC method 95–105% at release; 90–110% end of shelf life
6. Concentration chloride Titration method with silver nitrate. Concentration
at release 95–105% (4.61–5.10 mg/ml)
Concentration end of shelf life 90–110% (4.37–5.34 mg/ml)
7. Subvisible particles Ph. Eur. 2.9.19 According to method 1. Light obscuration particle
count test: ≤ 6000 particles/syringe for particles ≥ 10
μm and ≤ 600 particles/syringe for particles ≥25 μm
8. Closure integrity test Ph. Eur. 3.2.9./manipulated A dye immersion test with 0.1% methylene blue.
Immerse the syringes in a 1 g/L solution of methylene
blue and reduce the external pressure by 27 kPa for
10 min. Restore atmospheric pressure and leave the vials
immersed for 30 min. Rinse the outside of the syringes.
None of the vials contains any trace of colored solution.
9. Sterility Ph. Eur. 2.6.1 Sterile
10. Extractable volume Ph. Eur. 2.9.17 The volume extracted is not less than the nominal volume.
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The pH of the norepinephrine solution at t = 0 was 3.8,
3.3, and 3.1 for solutions without ascorbic acid or with 0.05%
or 0.10% ascorbic acid, respectively. After storage for
5 months, norepinephrine levels in these solutions were
100.4%, 95.4%, and 92.2% (relative to the concentration of
t = 0) respectively, as shown in Fig. 1. All results were within
specification (90–110%) at t = 5 months with less variability in
norepinephrine concentration during the study period when
no antioxidant was added to the solution. Based on these
results, it was decided to produce the batches for the stability
studies without an antioxidant. The following formulation was
produced: norepinephrine 0.11 mg/mL, sodium edetate
0.1 mg/mL, sodium chloride 8 mg/L with water for injections.
The solution was produced under GMP conditions.
Stability Study
The initial pH of 3.8–3.9 did not change significantly
during storage; after 12 months, a pH of 3.8 to 4.0 was found.
All solutions were clear at all points in time and the color of
the solution was < B9, the solutions were sterile, and the
number of particles was within limits. Table III gives an
overview of all results at t = 12 months for the three batches.
The norepinephrine recovery of the different batches is
shown in Fig. 2. When analyzing the t = 0 content of the
batches 1 and 2, it was found that there was less than 2% loss
during production and sterilization. Based on this result, the
overage of norepinephrine for batch 3 was reduced to 5%.
According to the ICH guideline on pharmaceutical develop-
ment, overages should be justified and proven safe (15). With
our new approach, we were able to reduce the overage by
50% to only 5% instead of 10%, whereas even the old
Fig. 1. Norepinephrine recovery (%) in formulation study
Table III. Results Stability Batches Norepinephrine Solution at t = 12 months
Test Acceptance criteria Batch 1 Batch 2 Batch 3
1. Clarity and degree of opalescence of the solution Clear solution Clear Clear Clear
2. Degree of coloration of the solution ≤ B9 B9 B9 B9
3. pH of the solution 3.6–6.0 3.8 3.8 3.8
4. Identity sodium Positive Positive Positive Positive
5. Concentration norepinephrine 95–105% at release;
90–110% end of shelf life.
98.8% 98.6% 99.3%
6. Concentration chloride Concentration at release 95–105%
Concentration end of shelf life 90–110%
100.6% 100.1% 101.5%
7. Subvisible particles ≤ 6000 particles/syringe for particles ≥ 10 μm















9. Sterility Sterile Sterile Sterile Sterile
10. Extractable volume The volume extracted is not less
than the nominal volume.
Complies Complies Complies
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formulation containing 10% overage was safely used for
decades. Moreover, our norepinephrine solution is adminis-
tered to the patient with an infusion pump, where the dose
will be titrated based on the clinical effect. So the solution can
be labeled as a 0.10 mg/mL norepinephrine solution.
The recoveries of norepinephrine (concentration at t = 0
was set to 100%) were 98.8%, 98.6%, and 99.3% for batches
1, 2, and 3 respectively at t = 12 months.
Our study showed that a 0.1-mg/mL norepinephrine
solution is stable without adding sodium metabisulfite as
an antioxidant. The concentration of 0.1 mg/mL was
chosen due to local use and the fact that the norepineph-
rine concentration does not affect the stability in a
significant way (10). In the formulation study, ascorbic
acid was shown to be unsuitable as an antioxidant for
norepinephrine solutions. Ascorbic acid seems to have a
destabilizing effect on norepinephrine based on the
significantly lower concentration of norepinephrine found.
Maybe it only has a synergistic stabilizing effect in
combination with other preservatives (10). Further inter-
ference of peaks of the ascorbic acid and norepinephrine
may have occurred. Since the solution without antioxidant
showed adequate stability, it was decided to discontinue
further analytical development on the solutions with
antioxidant. This is in line with the results of Brustugun
et al. (18) who found that bisulfite could have a
destabilizing effect on epinephrine during exposure to
light. A possible explanation could be the reaction of
epinephrine with various free radicals. In addition, several
studies have been performed in which dilutions of
commercial products (including concentration sodium
metabisulfite) were analyzed (19,20). Wolf et al. (19) show
the stability of norepinephrine solution after dilution with
0.9% NaCl to 0.1 and 0.01 mg/mL throughout storage at a
maximum of 8°C. Zenoni et al. (20) show stability up to
24 weeks for a 1:10 dilution of a commercially available
1.0-mg/mL norepinephrine solution at room temperature
and at 2–8°C. Rather than sodium metabisulfite, other
aspects of the formulation were probably having a more
pronounced effect on stabilizing the solution. Palazzolo
et al. (21) measured norepinephrine concentrations with-
out adding any preserving additives, but the solutions
were adjusted to three different pH values (1.96, 5.81, and
7.81) and stored at three different temperatures (− 60, 4,
and 22°C). Both acidic and basic solutions were stable in
the freezer, but at higher temperatures, degradation
occurred fast. The stability of the solution is probably
due to a synergistic effect of different stability parameters.
The pH was set to 3.8–3.9, not only norepinephrine is
more stable at acid conditions, but also the effect of
sodium edetate is pH dependent (10,22).
Another advantage of removing sodium metabisulfite
from the formulation is the fact that it can no longer cause
unwanted side effects. Sulfite-containing medications may
provoke adverse reactions with an immediate onset after
injection (12,13). The signs and symptoms of sulfite hyper-
sensitivity which may involve multiple target organs include
bronchoconstriction, wheezing, dyspnea, laryngeal edema,
swelling, and hypotension. Symptomology ranges in severity
from mild discomfort to life-threatening episodes and even
death (12). No accelerated stability study was performed, as
this was not necessary as there was no time pressure on the
development. And besides, norepinephrine solution is a well-
known commercially available product (Levophed®,
Arterenol®) with known degradation products (10). On the
other hand, the shelf life study was carried out in real lifetime,
with the shelf life claim never being longer than the
demonstrated results.
Another challenge could be to demonstrate the
closure integrity of the syringe. This was already per-
formed in another study where the primary container in
combination with the stopper and tip cap was investigated
for suitability as primary packaging material for pharma-
ceutical products. For the closure integrity test in this
study, positive control was included. This study shows all
adequately closed syringes (17). Based on these results
and the fact that the production process is similar for
norepinephrine syringes, it was expected the norepineph-
rine syringes would also meet the acceptance criteria for
closure integrity. This is confirmed in this study.
A weakness of the study could be that no impurities test
has been performed. This must be taken into account when
reviewing the results, although minimal effect is expected. For
the production of the solutions, Ph. Eur. compliant raw
materials were used which were within the acceptance limits
at the release of the batch.
This is also the case for the determination of possible
extractables from the primary container. This test is not
repeated based on the results of an extensive qualification
Fig. 2. norepinephrine recovery (%) in stability study
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program performed for the primary container which show
that the used cyclic olefin polymer syringes including stopper
and tip cap are suitable as primary packaging materials for
the production of water-soluble products with pH varying
from 3 to 9 with having low extractable profile (17).
Our results with norepinephrine can be considered as an
indication that also other catecholamines (like phenyleph-
rine) can be formulated into ready-to-administer syringes
without the use of sodium metabisulfite.
CONCLUSION
The norepinephrine (0.1 mg/mL) solution containing
sodium edetate and sodium chloride filled under nitrogen
gassing in syringes followed by heat sterilization is stable for
at least 12 months at room temperature when protected from
daylight. Such a formulation can be free of antioxidants, like
sodium metabisulfite or ascorbic acid.
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